Literature DB >> 9701699

Serum insulin-like growth factor-I, IGF binding protein-3 and IGFBP-3 protease activity after cranial irradiation.

V Tillmann1, S M Shalet, D A Price, J K Wales, L Pennells, J Soden, M S Gill, A J Whatmore, P E Clayton.   

Abstract

The relationship between peak growth hormone (GH), insulin-like growth factor I (IGF-I), IGF-I binding protein 3 (IGFBP-3) and IGFBP-3 protease activity was studied in 28 children and adolescents undergoing investigation of pituitary function 0.4-14.2 years after cranial or craniospinal irradiation for the treatment of CNS tumours distant from the hypothalamic-pituitary axis (n = 16) or prophylaxis against CNS leukaemia (n = 12). Seven out of 15 patients with GH deficiency (GHD) (defined as a peak GH concentration <7.5 ng/ml in a stimulation test) had IGF-I <-2 standard deviation score (SDS). None of the 28 patients had serum IGFBP-3 concentrations measured by radioimmunoassay (RIA) <-1.5 SDS with no difference between those with and without GHD. IGFBP-3 concentrations measured by RIA were strongly correlated to IGFBP-3 band density on Western ligand blot (WLB) (r = 0.71; p < 0.0001). IGFBP-3 protease activity was negatively correlated to IGFBP-3 by RIA (r = -0.55; p < 0.01) and to IGFBP-3 by WLB (r = -0.51; p < 0.01). Twenty-two patients had normal IGFBP-3 protease activity (<30% of the activity in pregnancy serum) indicating that serum IGFBP-3 protease activity does not account for the normal levels of IGFBP-3 in RIA. Low serum IGF-I but normal IGFBP-3 concentrations and in the majority normal IGFBP-3 protease activity was found in patients in the years after CNS irradiation. Neither serum IGF-I nor IGFBP-3 can be used as a reliable index of the development of radiation-induced GHD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9701699     DOI: 10.1159/000023237

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  5 in total

Review 1.  Pediatric brain tumor treatment: growth consequences and their management.

Authors:  Sogol Mostoufi-Moab; Adda Grimberg
Journal:  Pediatr Endocrinol Rev       Date:  2010-09

Review 2.  Advances in differential diagnosis and management of growth hormone deficiency in children.

Authors:  Camille Hage; Hoong-Wei Gan; Anastasia Ibba; Giuseppa Patti; Mehul Dattani; Sandro Loche; Mohamad Maghnie; Roberto Salvatori
Journal:  Nat Rev Endocrinol       Date:  2021-08-20       Impact factor: 43.330

Review 3.  Radiation-induced hypopituitarism after cancer therapy: who, how and when to test.

Authors:  Ken H Darzy
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2009-02

Review 4.  Growth Hormone Deficiency and Treatment in Childhood Cancer Survivors.

Authors:  Netanya I Pollock; Laurie E Cohen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-22       Impact factor: 5.555

Review 5.  Safety of growth hormone (GH) treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors-a review of research and clinical practice.

Authors:  Margaret C S Boguszewski; Adriane A Cardoso-Demartini; Cesar Luiz Boguszewski; Wassim Chemaitilly; Claire E Higham; Gudmundur Johannsson; Kevin C J Yuen
Journal:  Pituitary       Date:  2021-07-25       Impact factor: 4.107

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.